Lupin Ltd.
Clinical trials sponsored by Lupin Ltd., explained in plain language.
Global pharmaceutical company producing generic and branded medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New eye drug shows promise in battle against blinding disease
Disease control CompletedThis study tested a new medication, LUBT010, against the standard drug Lucentis for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. Six hundred participants received monthly injections into the eye for one year. The goal was to see if LUBT0…
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New study tracks Long-Term safety of muscle stiffness drug namuscla
Symptom relief CompletedThis study followed 53 adults with non-dystrophic myotonic disorders who were taking Namuscla (mexiletine) to manage muscle stiffness. Researchers monitored side effects and how often patients needed to reduce their dose or stop treatment over up to 36 months. The goal was to see…
Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC